Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Personalized treatment strategies in juvenile idiopathic arthritis starting TNF inhibitor therapy
2019-000889-38Phase 4Active
- Sponsor
- Oslo University Hospital
- Start
- Jun 2020
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of triamcinolone hexacetonide in juvenile idiopathic arthritis (JIA) (2 arms), sponsored by Oslo University Hospital. Primary endpoint: Sustained inactive disease from week 24 to week 36. Started Jun 2020; status: active.
02
Drugs
triamcinolone hexacetonide
03
Conditions
juvenile idiopathic arthritis (JIA)
Beyond the preview
Go deeper on 2019-000889-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-000889-38.